Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants
The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants
Sponsor: Mallinckrodt
Terminated
Enrollenment has been suspended due to poor enrollment
Other terminated trials from Mallinckrodt
Other Bronchopulmonary Dysplasia trials with similar outcome
Listed as NCT01748045, this PHASE2/PHASE3 trial focuses on Bronchopulmonary Dysplasia and remains terminated or withdrawn. Sponsored by Mallinckrodt, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
- Tufts Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .